Arcadia Biosciences, Inc. Quarterly Debt-to-equity in % from Q1 2016 to Q2 2024

Taxonomy & unit: ratio: %
Description: Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary: Arcadia Biosciences, Inc. quarterly Debt-to-equity history and growth rate from Q1 2016 to Q2 2024.
Arcadia Biosciences, Inc. Debt-to-equity for the quarter ending June 30, 2024 was 52.1 %, a 4.64% increase year-over-year.

Debt-to-equity, Quarterly (%)

Debt-to-equity, YoY Quarterly Growth (%)

Period	Value	YoY Chg	Change %	Date
Q2 2024	52.1	+2.31	+4.64%	Jun 30, 2024
Q1 2024	52.2	+8.28	+18.8%	Mar 31, 2024
Q4 2023	60	+26.8	+80.7%	Dec 31, 2023
Q3 2023	54.6	+20.1	+58.5%	Sep 30, 2023
Q2 2023	49.8	+11.9	+31.5%	Jun 30, 2023
Q1 2023	44	-3.94	-8.23%	Mar 31, 2023
Q4 2022	33.2	-20.9	-38.6%	Dec 31, 2022
Q3 2022	34.4	-24.8	-41.9%	Sep 30, 2022
Q2 2022	37.9	-37.1	-49.5%	Jun 30, 2022
Q1 2022	47.9	-46.2	-49.1%	Mar 31, 2022
Q4 2021	54.1	-82.5	-60.4%	Dec 31, 2021
Q3 2021	59.2	-155	-72.4%	Sep 30, 2021
Q2 2021	75	-131	-63.6%	Jun 30, 2021
Q1 2021	94	-114	-54.8%	Mar 31, 2021
Q4 2020	137	-148	-51.9%	Dec 31, 2020
Q3 2020	214	+8.46	+4.11%	Sep 30, 2020
Q2 2020	206	+21.8	+11.8%	Jun 30, 2020
Q1 2020	208	+5.76	+2.85%	Mar 31, 2020
Q4 2019	284	+80.1	+39.3%	Dec 31, 2019
Q3 2019	206	-22.1	-9.7%	Sep 30, 2019
Q2 2019	184	-40.7	-18.1%	Jun 30, 2019
Q1 2019	202	-10.2	-4.78%	Mar 31, 2019
Q4 2018	204	+40.2	+24.6%	Dec 31, 2018
Q3 2018	228	+60.4	+36%	Sep 30, 2018
Q2 2018	225	+60.3	+36.6%	Jun 30, 2018
Q1 2018	213	+74.5	+54%	Mar 31, 2018
Q4 2017	164	+45.7	+38.7%	Dec 31, 2017
Q3 2017	168	+65.7	+64.4%	Sep 30, 2017
Q2 2017	165	+72.4	+78.4%	Jun 30, 2017
Q1 2017	138	+53.3	+62.9%	Mar 31, 2017
Q4 2016	118			Dec 31, 2016
Q3 2016	102			Sep 30, 2016
Q2 2016	92.3			Jun 30, 2016
Q1 2016	84.7			Mar 31, 2016

* An asterisk sign (*) next to the value indicates that the value is likely invalid.